|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In children with abdominal pain and/or diarrhea, increased ESR, CRP and decreased albumin combined with a high fecal calprotectin level yields additional diagnostic value in screening potential patients with Crohn's disease.
|
30237086 |
2019 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD.
|
31148906 |
2019 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, PentraSorb CRP provides a novel, specific, and efficient CRP-binding resin that could be used in apheresis therapy for patients suffering from inflammatory diseases such as AMI, stroke, acute pancreatitis, and Crohn's disease.
|
30697961 |
2019 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> Baseline CRP level and CRP reduction rate might be clinical predictors for PNR or LOR to anti-TNF in patients with CD, and could guide proper therapeutic interventions in patients with CD.
|
31303093 |
2019 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the diagnostic performance as well as the relationship of C-reactive protein (CRP) and Crohn's Disease Activity Index (CDAI) with small bowel capsule endoscopy's (SBCE) inflammation scoring index, the Lewis Score (LS).
|
29697457 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CLE<sup>+</sup> patients showed an increased incidence of medical treatment escalation (P < .001; relative risk [RR] = 3.27) and transmural lesions (P = .025; RR = 1.70), whereas patients with CRP ≥5 mg/L had increased CD-related hospitalization and surgery (P = .020, RR = 2.71) at 1-year follow-up.
|
29108979 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
At week 44 of the maintenance study (52 weeks after treatment began), patients were evaluated for the primary endpoint of clinical remission (defined as a CD activity index score below 150 points), endoscopic markers of efficacy, and serum level of C-reactive protein.
|
29409871 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cytokines and CRP may serve as additional biomarkers for determining disease activity and evaluating treatment response in CD.
|
29466406 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Secondary outcomes included: the proportion of patients who responded to the reintroduction of immunosuppressant or biologic drugs, given as monotherapy or combination therapy; the proportion of patients who required surgery following relapse; the proportion of patients who required hospitalization for CD following relapse; the proportion of patients who developed new CD-related complications (e.g. fistula, abscesses, strictures) following relapse; the proportion of patients with elevated biomarkers of inflammation (CRP, fecal calprotectin) in those who stop and those who continue therapy; the proportion of patients with anti-drug antibodies and low serum trough drug levels; time to relapse; and the proportion of patients with adverse events, serious adverse events and withdrawal due to adverse events.
|
29756637 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI ≤ 150), C-reactive protein (CRP) ≤ 5 mg/L, faecal calprotectin (FC) ≤ 250 μg/g, and a composite endpoint of CDAI ≤ 150 and FC ≤ 250 μg/g.
|
29159893 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
FC is not better than CRP combined with HBI to predict endoscopic postoperative recurrence of CD.
|
30303822 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high IL-6 concentration on POD 1 is independently associated with the occurrence of postoperative IASCs in patients undergoing elective surgery for CD and could allow for earlier diagnosis and earlier intervention for IASCs compared with C-reactive protein.
|
29912382 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elderly patients with CD and patients with normal pretreatment CRP level may have a reduced response to MTX.
|
30516330 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to characterize pharmacokinetics (PK) of PF-04236921, a novel anti-interleukin-6 monoclonal antibody, and its pharmacokinetic/pharmacodynamic (PK/PD) relationship on serum C-reactive protein (CRP) in healthy volunteers and patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Crohn's disease (CD).
|
29776017 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this cohort study of 183 patients (109 Crohn's disease and 74 ulcerative colitis) on infliximab maintenance treatment at a tertiary referral center we correlated fecal calprotectin and C-reactive protein to trough levels (426 samples) at different time points during treatment.
|
29987967 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ninety-one CRP levels and 72 colonoscopies from 98 IBD patients [CD: n = 72 (73%)] were evaluated.
|
30006816 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine the efficacy of faecal calprotectin (FC) and C-reactive protein (CRP) as predictors of SBCE findings in suspected and known CD.
|
29466790 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crohn's disease activity index (CDAI) and Simple Endoscopic Score for Crohn's disease (SES-CD) for Crohn's disease (CD) or Mayo score and ulcerative colitis endoscopic index of severity (UCEIS) for ulcerative colitis (UC), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were used to evaluate the disease activity.
|
30558634 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data on fecal calprotectin, C-reactive protein, and other biomarkers from a population of 124 patients with suspected CD of the small bowel studied by CE and included in a PhD study were used to build a scoring index.
|
29489472 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In Crohn's disease, subtherapeutic adalimumab concentrations were associated with higher fecal calprotectin and CRP concentrations compared with therapeutic concentrations.
|
29623105 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study did not report on clinical response, CRP, quality of life or withdrawal due to AEs.One small study (N= 50) compared cannabis oil (15% cannabidiol and 4% THC) to placebo in participants with active CD.
|
30407616 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown.
|
29096949 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preoperative TSF and CRP independently affect iSSI in patients with CD undergoing intestinal resections.
|
30140279 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data from the ImageKids study to determine associations among mucosal, transmural healing and levels of calprotectin and C-reactive protein in children with CD.
|
29501599 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Endoscopic severity of ulcerative colitis (UC) and Crohn's disease (CD) was based on physician global assessment scores, substantiated by levels of fecal calprotectin and C-reactive protein at study inclusion.
|
29112087 |
2018 |